IASPP is over-expressed in human non-small cell lung cancer and regulates the proliferation of lung cancer cells through a p53 associated pathway

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Chen, Jinfeng ^a,b   Xie, Fei ^a   Zhang, Lijian ^a   Jiang, Wen G ^b  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; INHIBITOR OF APOPTOSIS PROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PROTEIN P53; SHORT HAIRPIN RNA; MESSENGER RNA; PPP1R13L PROTEIN, HUMAN; REPRESSOR PROTEIN; SIGNAL PEPTIDE; SMALL INTERFERING RNA; TP53 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL MOTILITY; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG NON SMALL CELL CANCER; WILD TYPE; BIOSYNTHESIS; CELL MOTION; GENE VECTOR; GENETICS; LENTIVIRINAE; LUNG TUMOR; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TIME; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LENTIVIRUS; LUNG NEOPLASMS; REPRESSOR PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78650609032     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-694     Document Type: Article

References (27)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000, 408:307-310. 10.1038/35042675, 11099028.
2. Bergamaschi D, Samuels Y, Jin B, Duraiingham S, Crook T, Lu X. ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol 2004, 24:1341-1350. 10.1128/MCB.24.3.1341-1350.2004, 321425, 14729977.
3. Hainaut P, Hernandez T, Rodriguze-Tome P, Flores T, IaRC MH. Database of p53 gene mutations in human tumours and cell lines: updated compilation, revised formats and new visualisation tools. Nucl Acides Res 1998, 26:205-213.
4. Sullivan A, Lu X. ASPP: a new family of oncogenes and tumour suppressor genes. Br J Cancer 2007, 96:196-200. 10.1038/sj.bjc.6603525, 2359998, 17211478.
5. Lowe SW, Jacks T, Housman DE, Ruley HE. Abrogation of oncogene-associated apoptosis allows transfoemation of p53-deficient cells. Proc Natl Sci USA 1994, 91:2026-2030.
6. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108:153-164. 10.1016/S0092-8674(02)00625-6, 11832206.
7. Lane DP, Lain S. Therapeutic exploitation of the p53 pathway. Trends Mol Med 2002, 8:s38-s42. 10.1016/S1471-4914(02)02309-2, 11927286.
8. Bell HS, Dufes C, O'Prey J, Crighton D, Bergamaschi D, Lu X, Schatzlein AG, Vousden KH, Ryan KM. A p53-derived apoptotic peptide derepresses p73 to cause tumour regression in vivo. J Clin Invest 2007, 117:1008-1018. 10.1172/JCI28920, 1810568, 17347683.
9. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Sal GD, Syed N, Smith P, Gasco M, Crook T, Lu X. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 2006, 38:1133-1141. 10.1038/ng1879, 16964264.
10. Samuels-Lev Y, O'connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, Carmpargue I, Naumovski L, Crook T, Lu X. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001, 83:781-794.
11. Ahn J, Byeon IL, Byeon C, Gronenborn AM. Insight into the structural basis of pro- and antiapoptotic p53 modulation by ASPP proteins. J Biol Chem 2009, 284:13812-13822. 10.1074/jbc.M808821200, 2679482, 19246451.
12. Zhang X, Diao S, Rao Q, Xing H, Liu H, Liao X, Wang M, Wang J. Identification of a novel isoform of iASPP and its interaction with p53. J Mol Biol 2007, 368:1162-1171. 10.1016/j.jmb.2007.03.001, 17391696.
13. Liu H, Wang M, Diao S, Rao Q, Zhang X, Xing H, Wang J. siRNA-mediated down-regulation of iASPP promotes apoptosis induced by etoposide and daunorubicin in leukemia cells expressing wild-type p53. Leuk Res 2009, 33:1243-1248. 10.1016/j.leukres.2009.02.016, 19299014.
14. Bergamaschi D, Samuels Y, O'Nail NJ, Trigiante G, Crook T, Hsieh J, O'Connor DJ, Zhong S, Campargue I, Tomlinson ML, Kuwabara PE, Lu X. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 2003, 33:162-167. 10.1038/ng1070, 12524540.
15. Liu ZJ, Zhang Y, Zhang XB, Yang X. Abnormal mRNA expression of ASPP members in leukemia cell lines. Leukemia 2004, 18:880. 10.1038/sj.leu.2403300, 14973501.
16. Zhang X, Wang M, Zhou C, Chen S, Wang J. The expression of iASPP in acute leukemias. Leuk Res 2005, 29:179-183. 10.1016/j.leukres.2004.07.001, 15607367.
17. Agirre X. ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promotor in acute lymphoblastic leukemia. Oncogene 2006, 25:1862-1870. 10.1038/sj.onc.1209236, 16314841.
18. Lossos IS, Natkunam Y, Levy R, Lopez CD. Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinical outcome. Leuk Lymphoma 2002, 43:2309-2317. 10.1080/1042819021000040017, 12613517.
19. Liu Z, Cai Y, Hou L, Gao X, Xin H, Lu X, Zhong S, Gu S, Chen J. Effect of RNA interference of iASPP on the Apoptosis in MCF-7 breast cancer cells. Cancer Invest 2008, 26:878-882. 10.1080/07357900801965042, 18798069.
20. Sua D, Mab S, Liu P, Jiang Z, Lv W, Zhang Y, Deng Q, Smitha S, Yu H. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007, 56:281-288. 10.1016/j.lungcan.2006.12.002, 17222938.
21. Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene 2009, 27:S71-S83.
22. Tidow H, Veprintsev DB, Freund SMV, Fersht AR. Effects of oncogenic mutations and DNA response elements on the binding of p53 to p53 binding protein2(53BP2). J Biol Chem 2006, 281:32526-32533. 10.1074/jbc.M604725200, 16887812.
23. Guilbert JJ. The world health report 2002- reducing risks, promoting healthy life. Edu health (Abingdon) 2003, 16:230.
24. Bell HS, Ryan KM. iASPP Inhibition: increased options in targeting the p53 family for cancer therapy. Cancer Res 2008, 68:4959-4962. 10.1158/0008-5472.CAN-08-0182, 18593889.
25. Robinson RA, Lu X, Jones EY, Siebold C. Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73. Cell 2008, 16:259-267.
26. Yan J, Yun H, Yang Y, Jing B, Feng C, Song-bin F. Upregulation of BNIP3 promotes apoptosis of lung cancer cells that were induced by p53. Biochem Biophys Res Commun 2006, 346:501-507. 10.1016/j.bbrc.2006.05.160, 16765911.
27. Tokalov SV, Abolmaali ND. Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment. BMC cancer 2010, 10:57. 10.1186/1471-2407-10-57, 2841137, 20178585.